BioCardia Inc. Aktie News

SUNNYVALE, Calif., 23. Sept. 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], ein weltweit führendes Unternehmen für zelluläre und zellabgeleitete Therapeutika zur Behandlung von Herz-Kreislauf- und Lungenerkrankungen, gab heute ein Update zu kurzfristigen Meilensteinen.

SUNNYVALE, Calif., 24. Aug. 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], ein weltweit führendes Unternehmen im Bereich zellulärer und zellabgeleiteter Therapeutika zur Behandlung von Herz‑ und Lungenerkrankungen, gibt heute den Erhalt der FDA‑Bestätigung über das Ergebnis seiner Vorbesprechung zum Helix Transendokardialen Applikationskatheter‑System (Helix) bekannt.

SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company's Chief Executive Officer, Peter Altman, issued the following letter to shareholders.

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales.

SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic hear...

– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted a...

SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The ...